Discover

NTRA
Natera, Inc.
332.03
2 x 304.21
2 x 348.08
bid
ask
+
7.19
2.21%
2 @ 07:59 PM
332.88 +0.85 (0.26%)
Ytd44.93%
1y105.02%
320.41
day range
332.98
160.21
52 week range
332.03
Open321.61Prev Close324.84Low320.41High332.98Mkt Cap47.86B
Vol1.21MAvg Vol1.45MEPS-1.39P/EN/AForward P/E-3722.31
Beta1.51Short Ratio3.77Inst. Own96.57%DividendN/ADiv YieldN/A
Ex Div DateN/AEarning11-0550-d Avg270.34200-d Avg228.661yr Est336.74
Earning
DateForEstimateReportedSurprisesurprise %
2026-11-052026-09-0.22N/AN/AN/A
2026-08-062026-06-0.49-0.470.024.85%
2026-05-072026-03-0.54-0.56-0.02-3.28%
2026-02-262025-12-0.510.350.86168.35%
2025-11-062025-09-0.39-0.64-0.25-65.94%
2025-08-072025-06-0.62-0.74-0.12-20.24%
Upgrade / Downgrade
DateFirmActionFromTo
2026-08-13CitigroupUpgradeBuyBuy
2026-08-12Piper SandlerUpgradeOverweightOverweight
2026-08-12Stephens & Co.UpgradeOverweightOverweight
2026-08-12GuggenheimUpgradeBuyBuy
2026-08-07TD CowenUpgradeBuyBuy
2026-08-07CitigroupUpgradeBuyBuy
Profile
Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide. It offers Signatera, a personalized ctDNA blood test for MRD assessment, early recurrence monitoring, and evaluation of treatment response in patients previously diagnosed with cancer; Latitude, a blood-based MRD test for colorectal cancer; Altera, a tissue based comprehensive genomic profiling test; and Empower, a hereditary cancer screening test. The company also provides Panorama, a non-invasive prenatal test; Horizon, a carrier screening test; Fetal Focus, a single-gene NIPT, or sgNIPT, that screens for 21 single-gene inherited conditions; and Vistara, a single-gene NIPT, which screens for 25 single-gene conditions. In addition, it offers Anora, which tests and analyzes miscarriage tissue from women who have experienced one or more pregnancy losses; Empower, a hereditary cancer screening test; Prospera, a test to assess active rejection in patients who have undergone solid organ transplantation; Renasight, a kidney gene panel test; and Constellation software, a cloud-based distribution model. Further, the company provides NateraCore, a platform to support the patient and provider experience; phlebotomy services; and EMR integration services. The company serves independent laboratories, national and regional reference laboratories, medical centers and physician practices for its screening tests, research laboratories, and pharmaceutical companies through its direct sales force and laboratory distribution partners, as well as Constellation licensees under its cloud-based distribution model. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays for clinical and commercial use. The company has a collaboration with Diakonos Oncology Corp. to assess molecular response in patients with refractory melanoma. The company was formerly known as Gene Security Network, LLC and changed its name to Natera, Inc. in January 2012. Natera, Inc. was founded in 2003 and is headquartered in Austin, Texas.
Insider Holder
DateNameRelationQuantityDescription
2026-06-25BAYNES ROY DDirector20.16KStock Award(Grant)
2026-06-25BOTHA ROELOF FREDERICKDirector1.08MStock Award(Grant)
2026-08-03BROPHY MICHAEL BURKESChief Financial Officer51.64KSale
2026-08-02CHAPMAN STEVEN LEONARDChief Executive Officer99.90KSale
2026-08-02FESKO JOHNPresident183.77KSale
2025-04-24HEALY JAMES IDirector1.60MStock Award(Grant)
Institution Ownership
Report DateOrganizationPositionValuePercentage
2026-06-29JPMORGAN CHASE & CO12.87M4.27B8.93%
2026-06-29Blackrock Inc.10.91M3.62B7.57%
2026-06-29Price (T.Rowe) Associates Inc9.02M3.00B6.26%
2026-06-29Vanguard Capital Management LLC6.23M2.07B4.32%
2026-06-29Vanguard Portfolio Management LLC5.78M1.92B4.01%
2026-06-29FMR, LLC5.45M1.81B3.78%
Fund Ownership
Report DateOrganizationPositionValuePercentage
2026-03-30JPMorgan Trust II-JPMorgan Large Cap Growth Fund6.03M2.00B4.18%
2026-03-30VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund4.21M1.40B2.92%
2026-03-30VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund3.05M1.01B2.12%
2026-03-30VANGUARD INDEX FUNDS-Vanguard Small-Cap Growth Index Fund1.71M567.50M1.19%
2026-06-29Fidelity Contrafund1.62M536.97M1.12%
2026-03-30VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund1.54M512.65M1.07%